Stock Update (NYSE:BMY): Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program

[Business Wire] – Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of Bristol-Myers Squibb’s Immuno-Oncology Rare . . . → Read More: Stock Update (NYSE:BMY): Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S. Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma